Vivos Therapeutics, Inc. (VVOS) — SEC Filings
Vivos Therapeutics, Inc. (VVOS) — 50 SEC filings. Latest: 8-K (Apr 15, 2026). Includes 28 8-K, 6 10-Q, 3 SC 13G/A.
View Vivos Therapeutics, Inc. on SEC EDGAR
Overview
Vivos Therapeutics, Inc. (VVOS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 15, 2026: Vivos Therapeutics, Inc. filed an 8-K on April 15, 2026, reporting on its Results of Operations and Financial Condition. The filing also includes Financial Statements and Exhibits. Specific financial details and performance metrics are expected to be found within the attached exhibits.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant filing sentiment for Vivos Therapeutics, Inc. is neutral.
Filing Type Overview
Vivos Therapeutics, Inc. (VVOS) has filed 28 8-K, 6 10-Q, 2 DEF 14A, 1 8-K/A, 2 10-K, 2 S-1/A, 2 S-1, 3 SC 13G/A, 1 DEFA14A, 2 SC 13G, 1 10-K/A with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of VVOS's 44 recent filings, 2 were flagged as high-risk, 23 as medium-risk, and 19 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $13.619M |
| Net Income | -$14.276M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $3.087M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | $8.379M |
Key Executives
- R. Kirk Huntsman
- Bradford Amman
- Barry I. Grossman, Esq.
- Dr. Michael J. Rieder
- Barry I. Grossman
- Lawrence A. Rosenbloom
Industry Context
Vivos Therapeutics operates in the rapidly growing sleep disorder treatment market, particularly focusing on non-CPAP solutions. The industry is characterized by increasing awareness of sleep apnea's health implications and a demand for innovative treatments. Competition includes established medical device companies and emerging biotech firms offering alternative therapies.
Top Tags
8-k (8) · financials (7) · material-agreement (5) · 10-Q (5) · filing (4) · medical-devices (4) · equity-sale (4) · Vivos Therapeutics (4) · financial-obligation (3) · corporate-governance (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue | $13.619M | Increased 20.17% for the nine months ended September 30, 2025, from $11.333M in 2024. |
| Net Loss | $14.276M | Widened significantly for the nine months ended September 30, 2025, from $8.309M in 2024. |
| Service Revenue | $7.726M | Increased from $5.725M for the nine months ended September 30, 2025. |
| General and Administrative Expenses | $19.181M | Increased from $13.531M for the nine months ended September 30, 2025. |
| Cash and Cash Equivalents | $3.087M | Decreased from $6.260M at December 31, 2024, to September 30, 2025. |
| Long-term Debt | $8.379M | Increased from $0 at December 31, 2024, to September 30, 2025, primarily due to SCN acquisition financing. |
| Cash Payment for Acquisition | $5.135M | Net payment for The Sleep Center of Nevada acquisition in June 2025. |
| Common Stock Shares Outstanding | 8,988,106 | As of November 14, 2025, indicating dilution. |
| Proposed shares for 2024 Omnibus Equity Incentive Plan | 4,100,000 | Increase from 1,600,000 shares, representing a 156% increase in authorized shares. |
| Shares of Common Stock outstanding | 7,504,807 | As of the September 8, 2025 Record Date, each share entitles the holder to one vote. |
| Beneficial holders of Common Stock | 9,813 | Approximate number of beneficial holders as of the Record Date. |
| Date of Annual Meeting | November 4, 2025 | The virtual meeting will be held at 10:00 a.m. Mountain Time. |
| Record Date | September 8, 2025 | Stockholders of record on this date are entitled to vote at the Annual Meeting. |
| Number of directors to be elected | 6 | All six incumbent directors are nominated for re-election. |
| Increase in authorized shares | 2,500,000 | The difference between the proposed 4,100,000 shares and the current 1,600,000 shares in the 2024 Plan. |
Frequently Asked Questions
What are the latest SEC filings for Vivos Therapeutics, Inc. (VVOS)?
Vivos Therapeutics, Inc. has 50 recent SEC filings from Feb 2024 to Apr 2026, including 28 8-K, 6 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VVOS filings?
Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Vivos Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Vivos Therapeutics, Inc. (VVOS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Vivos Therapeutics, Inc.?
Key financial highlights from Vivos Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for VVOS?
The investment thesis for VVOS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Vivos Therapeutics, Inc.?
Key executives identified across Vivos Therapeutics, Inc.'s filings include R. Kirk Huntsman, Bradford Amman, Barry I. Grossman, Esq., Dr. Michael J. Rieder, Barry I. Grossman and 1 others.
What are the main risk factors for Vivos Therapeutics, Inc. stock?
Of VVOS's 44 assessed filings, 2 were flagged high-risk, 23 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Vivos Therapeutics, Inc.?
Forward guidance and predictions for Vivos Therapeutics, Inc. are extracted from SEC filings as they are enriched.